Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for Benitec Biopharma in a research report issued to clients and investors on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.28). The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($1.19) EPS.
Other research analysts also recently issued research reports about the stock. Baird R W raised shares of Benitec Biopharma to a "strong-buy" rating in a report on Thursday, December 12th. Robert W. Baird began coverage on Benitec Biopharma in a research report on Friday, December 13th. They set an "outperform" rating and a $30.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $28.00 target price on shares of Benitec Biopharma in a report on Monday, March 24th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Benitec Biopharma has an average rating of "Buy" and a consensus target price of $24.43.
Read Our Latest Analysis on BNTC
Benitec Biopharma Stock Performance
BNTC stock traded down $0.04 during trading on Thursday, hitting $11.99. 21,983 shares of the company's stock traded hands, compared to its average volume of 55,732. Benitec Biopharma has a 52 week low of $4.75 and a 52 week high of $16.90. The stock has a market capitalization of $281.06 million, a price-to-earnings ratio of -7.94 and a beta of 0.76. The business has a fifty day simple moving average of $12.47 and a 200 day simple moving average of $11.33.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.19.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. grew its position in shares of Benitec Biopharma by 269.0% during the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after buying an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Benitec Biopharma by 198.5% in the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock worth $33,268,000 after acquiring an additional 1,739,904 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in Benitec Biopharma by 134.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock worth $24,913,000 after acquiring an additional 1,131,129 shares during the period. Infinitum Asset Management LLC bought a new position in Benitec Biopharma during the 4th quarter worth about $2,652,000. Finally, Suvretta Capital Management LLC increased its position in Benitec Biopharma by 1.5% during the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after purchasing an additional 130,956 shares during the period. 52.19% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Benitec Biopharma
In other news, Director Suvretta Capital Management, L purchased 900,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the acquisition, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. This trade represents a 11.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 1.30% of the company's stock.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Further Reading
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
